title: Comparison of electrodiagnostic abnormalities and criteria in a cohort of patients with chronic inflammatory demyelinating polyneuropathy.
abstract: BACKGROUND
  Current electrodiagnostic criteria for chronic inflammatory demyelinating polyneuropathy (CIDP) are research oriented favoring specificity over sensitivity. Application of such criteria in clinical practice may miss the diagnosis in potentially treatable patients.
  
  
  OBJECTIVE
  To analyze the electrophysiologic abnormalities in a cohort of patients with clinically defined CIDP, to compare these data with published electrodiagnostic criteria, and to identify a set of abnormalities that is shared by all patients with CIDP.
  
  
  METHODS
  Retrospective medical record review.
  
  
  METHODS
  Academically based neuromuscular clinic. Patients Fifteen patients with clinically diagnosed relapsing sensorimotor CIDP.
  
  
  METHODS
  Administration of intravenous immunoglobulin or prednisone.
  
  
  METHODS
  Electrodiagnostic studies.
  
  
  RESULTS
  All patients had electrodiagnostic abnormalities in at least 3 nerves with possible partial conduction block or demyelinating range abnormalities in at least 1 nerve. The diagnostic sensitivities of 5 published CIDP criteria were as follows: the Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force (40%), Saperstein et al (47%), Nicolas et al (53%), Hughes et al for the Inflammatory Neuropathy Cause and Treatment Group (60%), and Thaisetthawatkul et al (70%).
  
  
  CONCLUSIONS
  Current electrodiagnostic criteria for CIDP are insensitive and may fail to diagnose the condition in a substantial number of patients. More inclusive criteria that allow identification of patients in routine clinical practice are needed.
authors.affiliation: Peripheral Neuropathy Center, Department of Neurology, Weill Medical College of Cornell University, New York, NY 10022, USA. pam2003@med.cornell.edu
authors.forename: Paul
authors.initials: P
authors.lastname: Magda
authors.forename: Norman
authors.initials: N
authors.lastname: Latov
authors.forename: Thomas H
authors.initials: TH
authors.lastname: Brannagan
authors.forename: Louis H
authors.initials: LH
authors.lastname: Weimer
authors.forename: Russell L
authors.initials: RL
authors.lastname: Chin
authors.forename: Howard W
authors.initials: HW
authors.lastname: Sander
mesh_terms: D000200:Action Potentials; D000328:Adult; D000368:Aged; D015331:Cohort Studies; D004185:Disability Evaluation; D004568:Electrodiagnosis; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D018482:Muscle, Skeletal / Q000503:physiopathology; D020277:Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / Q000175:diagnosis* / Q000188:drug therapy / Q000503:physiopathology; D011241:Prednisone / Q000627:therapeutic use; D012189:Retrospective Studies
chemical_list: D005938:Glucocorticoids; D016756:Immunoglobulins, Intravenous; D011241:Prednisone